Jazz Pharmaceuticals

Jazz Pharma submits Vyxeos MAA to EMA for high-risk AML

Friday, November 3, 2017

Jazz Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to the EMA‘s Committee for Medicinal Products for Human Use (CHMP) for Vyxeos (daunorubicin and cytarabine) powder for concentrate for infusion to treat adults with high-risk acute myeloid leukemia (AML) defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

[Read More]

Alizé Pharma II acquired by Jazz Pharmaceuticals

Monday, May 16, 2016

A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million ($20.4 million), including an upfront payment of €8 million and potential payments of up to €10 million related to regulatory milestones. The transaction did not involve the transfer of any employees from the Alizé Pharma group to Jazz Pharmaceuticals.

[Read More]

Jazz, Concert partner to develop deuterium-modified sodium oxybate

Wednesday, February 27, 2013

Jazz Pharmaceuticals, an Irish specialty biopharmaceutical company focused on unmet medical needs, and Concert Pharmaceuticals, a Lexington, Mass.-based clinical stage biotechnology company, have signed an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.   

[Read More]